PITTSBURGH, Sept. 29 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. (NYSE: MYL) today announced that the U.S. Food and Drug Administration has granted final approval for Mylan Pharmaceuticals' Abbreviated New Drug Application for Bromocriptine Mesylate Tablets USP, 2.5 mg. Bromocriptine Tablets are the generic version of Novartis Pharmaceuticals, Parlodel^® Tablets.

The product will be shipped immediately.

Mylan Laboratories Inc. is a leading pharmaceutical company with four subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc., UDL Laboratories Inc. and Mylan Bertek Pharmaceuticals Inc., that develop, manufacture and market an extensive line of generic and proprietary products.

This press release includes statements that constitute "forward-looking statements," including with regard to the immediate shipment of Bromocriptine Mesylate USP Tablets. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the possible negative effects of any interruption of manufacture of the product at the Company's facility; uncertainties regarding market acceptance and demand for the product; dependence on third-party suppliers and distributors for raw materials; and the other risks detailed in the Company's filings with the Securities and Exchange Commission. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

For more information about Mylan, visit www.mylan.com

SOURCE Mylan Laboratories Inc.
09/29/2004
CONTACT: Heather Bresch, Public Relations, or Kris King, Investor Relations, of Mylan Laboratories Inc., +1-724-514-1800
Web site: http://www.mylan.com